NCT03049462 2026-03-11
The Physiological Responses and Adaptation of Brown Adipose Tissue to Chronic Treatment With Beta3-Adrenergic Receptor Agonists
National Institutes of Health Clinical Center (CC)
Phase 1 Recruiting
Clinical Trials
8 trialsNCT07261683 2025-12-19
Phase II Study of Weekly Paclitaxel/Nab-Paclitaxel, Pembrolizumab, and Mirabegron for Recurrent Ovarian Cancer
Obstetrics & Gynecology Hospital of Fudan University
Phase 2 Recruiting
NCT06791460 2025-03-18
Pegylated Liposomal Doxorubicin Plus Adebrelimab With or Without Mirabegron in Relapsed Ovarian Cancer
Obstetrics & Gynecology Hospital of Fudan University
Phase 2/3 Recruiting
NCT06534762 2024-08-02
Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study
Zhejiang Provincial People's Hospital
Phase 2 Recruiting
NCT05779514 2023-03-22
Effect of Mirabegron on Promoting Brown Adipose Tissue Activation
Zhejiang Provincial People's Hospital
Phase NA Unknown
NCT03600766 2019-09-04
Mirabegron for Treatment of Erectile Dysfunction in Patients With LUTS Secondry to BPH: A Randomized Study
Mansoura University
Phase 2 Unknown
NCT00750620 2013-09-05
A Pharmacokinetic Study of YM178 in Normal Subjects and Those With Mild, Moderate, and Severe Renal Impairment
Astellas Pharma Inc
Phase 1 Completed
NCT01579461 2013-09-05
A Study to Investigate the Effect of Mirabegron (YM178) on Subjects With Mild or Moderate Hepatic Impairment Compared to Healthy Subjects
Astellas Pharma Inc
Phase 1 Completed